- Home
- PCYO vs NBTX Comparison
PCYO vs NBTX Comparison
Compare PCYO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- NBTX
- Stock Information
- Founded
- PCYO 1976
- NBTX 2003
- Country
- PCYO United States
- NBTX France
- Employees
- PCYO N/A
- NBTX N/A
- Industry
- PCYO Water Supply
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- PCYO Utilities
- NBTX Health Care
- Exchange
- PCYO Nasdaq
- NBTX Nasdaq
- Market Cap
- PCYO 242.7M
- NBTX 211.9M
- IPO Year
- PCYO N/A
- NBTX 2020
- Fundamental
- Price
- PCYO $10.13
- NBTX $7.91
- Analyst Decision
- PCYO
- NBTX Strong Buy
- Analyst Count
- PCYO 0
- NBTX 1
- Target Price
- PCYO N/A
- NBTX $8.00
- AVG Volume (30 Days)
- PCYO 42.1K
- NBTX 10.5K
- Earning Date
- PCYO 07-09-2025
- NBTX 09-17-2025
- Dividend Yield
- PCYO N/A
- NBTX N/A
- EPS Growth
- PCYO 123.89
- NBTX N/A
- EPS
- PCYO 0.56
- NBTX N/A
- Revenue
- PCYO $27,447,000.00
- NBTX N/A
- Revenue This Year
- PCYO N/A
- NBTX N/A
- Revenue Next Year
- PCYO N/A
- NBTX $74.67
- P/E Ratio
- PCYO $17.93
- NBTX N/A
- Revenue Growth
- PCYO 40.36
- NBTX N/A
- 52 Week Low
- PCYO $9.65
- NBTX $2.76
- 52 Week High
- PCYO $14.63
- NBTX $8.47
- Technical
- Relative Strength Index (RSI)
- PCYO 50.97
- NBTX 73.17
- Support Level
- PCYO $9.80
- NBTX $6.97
- Resistance Level
- PCYO $10.48
- NBTX $8.47
- Average True Range (ATR)
- PCYO 0.22
- NBTX 0.40
- MACD
- PCYO 0.05
- NBTX 0.07
- Stochastic Oscillator
- PCYO 57.83
- NBTX 76.47
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.